https://www.vjhemonc.com/video/pwsulljtyro-clonal-hematopoiesis-donor-derived-leukemia-insights-from-an-eha-ebmt-joint-session/ 2026-07-03T11:21:56+00:00 https://www.vjhemonc.com/video/lnf9qmvzrok-guidance-for-community-oncologists-navigating-the-aml-treatment-landscape/ 2026-07-03T11:21:57+00:00 https://www.vjhemonc.com/video/c3m2b7ee7mw-updated-eln-recommendations-for-mrd-monitoring-in-aml-key-insights-and-takeaways/ 2026-07-03T11:21:57+00:00 https://www.vjhemonc.com/video/pr2qwwf0jpa-insights-into-a-study-validating-the-icc-hierarchical-classification-in-secondary-aml/ 2026-07-03T11:21:57+00:00 https://www.vjhemonc.com/video/fyaba3_l0zq-nipocalimab-shows-pharmacodynamic-activity-in-warm-autoimmune-hemolytic-anemia/ 2026-07-03T11:21:59+00:00 https://www.vjhemonc.com/video/16-yunny-tw-3-year-commodore-1-data-support-long-term-crovalimab-in-pnh/ 2026-07-03T11:21:59+00:00 https://www.vjhemonc.com/video/lvw6qrwuysm-when-to-suspect-and-test-for-paroxysmal-nocturnal-hemoglobinuria/ 2026-07-03T11:21:59+00:00 https://www.vjhemonc.com/video/yb7jv0ntxys-final-cll-frail-analysis-supports-acalabrutinib-in-elderly-and-frail-patients-with-cll/ 2026-07-03T11:22:01+00:00 https://www.vjhemonc.com/video/ahpex7csoiq-practical-considerations-for-using-acalabrutinib-in-elderly-patients-with-cll/ 2026-07-03T11:22:01+00:00 https://www.vjhemonc.com/video/wzp7_9vd0v0-managing-cardiovascular-toxicity-with-first-line-btk-inhibitors-in-cll/ 2026-07-03T11:22:01+00:00 https://www.vjhemonc.com/video/7p9venuowqe-why-elderly-and-frail-patients-need-greater-representation-in-cll-clinical-trials/ 2026-07-03T11:22:02+00:00 https://www.vjhemonc.com/video/xs70ugnx2x0-the-impact-of-rusfertide-on-pv-related-symptoms-patient-reported-outcomes-in-the-verify-trial/ 2026-07-03T11:22:03+00:00 https://www.vjhemonc.com/video/hwsbta7wtoc-the-importance-of-addressing-cardiovascular-risk-in-mpns-unmet-needs-in-this-space/ 2026-07-03T11:22:03+00:00 https://www.vjhemonc.com/video/8u1fzcuo00c-the-rationale-for-exploring-xpo1-inhibition-in-myelofibrosis/ 2026-07-03T11:22:04+00:00 https://www.vjhemonc.com/video/c_tpb6ovowm-managing-tp53-mutated-mds-current-strategies-and-remaining-therapeutic-challenges/ 2026-07-03T11:22:04+00:00 https://www.vjhemonc.com/video/2ccrzqqmra8-recent-advances-in-frontline-treatment-approaches-for-patients-with-low-risk-mds/ 2026-07-03T11:22:04+00:00 https://www.vjhemonc.com/video/m9esiiumup4-updates-on-the-quantum-first-trial-quizartinib-plus-chemotherapy-in-newly-diagnosed-flt3-aml/ 2026-07-03T11:22:05+00:00 https://www.vjhemonc.com/video/9je47rwvhru-phase-i-study-of-etentamig-in-rr-al-amyloidosis-safety-efficacy-data/ 2026-07-03T11:22:05+00:00 https://www.vjhemonc.com/video/cw5lsielrno-practical-considerations-for-switching-from-ruxolitinib-to-momelotinib-in-patients-with-mf/ 2026-07-03T11:22:06+00:00 https://www.vjhemonc.com/video/pjeaploive4-practical-strategies-to-better-prevent-and-manage-infections-in-multiple-myeloma/ 2026-07-03T11:22:07+00:00 https://www.vjhemonc.com/video/harz9n4rxuu-insights-into-the-mechanisms-and-treatment-responses-of-the-pim-1-kinase-inhibitor-nuvisertib-in-mf/ 2026-07-03T11:22:07+00:00 https://www.vjhemonc.com/video/nhe0z01_yku-an-ngs-liquid-biopsy-approach-vs-standard-bone-marrow-fish-for-genomic-characterization-in-myeloma/ 2026-07-03T11:22:07+00:00 https://www.vjhemonc.com/video/vhzdg2tolqo-the-value-of-using-ctdna-for-mrd-detection-in-hodgkin-lymphoma-ongoing-work-in-the-field/ 2026-07-03T11:22:08+00:00 https://www.vjhemonc.com/video/j6_w0bdvyu0-shorespan-017-extension-data-support-the-long-term-safety-of-bomedemstat-in-mf-and-et/ 2026-07-03T11:22:08+00:00 https://www.vjhemonc.com/video/nvntjtkizik-a-modern-individualized-approach-to-managing-polycythemia-vera/ 2026-07-03T11:22:08+00:00 https://www.vjhemonc.com/video/2ocgu3jzo_c-rusfertide-reduces-cytoreductive-therapy-requirements-in-polycythemia-vera/ 2026-07-03T11:22:09+00:00 https://www.vjhemonc.com/video/fxffnwg9xe8-predictors-of-infection-in-patients-with-myelofibrosis-receiving-ruxolitinib/ 2026-07-03T11:22:10+00:00 https://www.vjhemonc.com/video/o4n0tksia-e-splicing-mutations-predict-poorer-outcomes-with-ruxolitinib-in-myelofibrosis/ 2026-07-03T11:22:10+00:00 https://www.vjhemonc.com/video/dvf6dljqscs-should-routine-ch-screening-of-donors-become-standard-practice-across-transplant-programs/ 2026-07-03T11:22:11+00:00 https://www.vjhemonc.com/video/di02eiaklqo-considerations-when-screening-donors-for-ch-mutations-to-assess-the-risk-of-donor-derived-leukemia/ 2026-07-03T11:22:11+00:00 https://www.vjhemonc.com/video/92gvccwwsmw-enable-study-highlights-the-promise-of-elvn-001-in-chronic-phase-cml/ 2026-07-03T11:22:12+00:00 https://www.vjhemonc.com/video/ukapyje0hg4-can-the-gut-microbiome-predict-response-to-car-t-cell-therapy-in-lymphoma/ 2026-07-03T11:22:12+00:00 https://www.vjhemonc.com/video/c0qxfqjr-_4-using-crispr-to-identify-the-next-generation-of-car-t-cell-targets/ 2026-07-03T11:22:12+00:00 https://www.vjhemonc.com/video/lmsxo6iv_tw-how-single-cell-technologies-are-reshaping-lymphoma-immunotherapy/ 2026-07-03T11:22:13+00:00 https://www.vjhemonc.com/video/f_uty2kf8-o-idh1-targeted-therapy-continues-to-reshape-aml-treatment/ 2026-07-03T11:22:14+00:00 https://www.vjhemonc.com/video/u4opj71ih3o-fixed-duration-pirtobrutinib-plus-obinutuzumab-shows-promise-in-frontline-cll/ 2026-07-03T11:22:14+00:00 https://www.vjhemonc.com/video/5zhy6ils8xa-the-growing-role-of-fixed-duration-therapy-in-chronic-lymphocytic-leukemia/ 2026-07-03T11:22:15+00:00 https://www.vjhemonc.com/video/ok5f2mrio-targeting-mutant-calr-in-mf-and-et-the-therapeutic-potential-of-inca33989/ 2026-07-03T11:22:16+00:00 https://www.vjhemonc.com/video/d0sc4c59eju-which-emerging-therapeutic-approaches-have-the-potential-to-transform-patient-outcomes-in-mf/ 2026-07-03T11:22:16+00:00 https://www.vjhemonc.com/video/pxjqgtjfi_8-optimizing-anemia-management-in-lower-risk-myelodysplastic-syndromes/ 2026-07-03T11:22:16+00:00 https://www.vjhemonc.com/video/kr5nxwzsidm-real-world-data-support-olutasidenib-after-venetoclax-in-idh1-mutated-aml/ 2026-07-03T11:22:17+00:00 https://www.vjhemonc.com/video/aanwbp_1fq8-could-luspatercept-modify-disease-in-lower-risk-myelodysplastic-syndromes/ 2026-07-03T11:22:17+00:00 https://www.vjhemonc.com/video/puome8ryonm-factoring-quality-of-life-into-treatment-decisions-for-patients-with-aml/ 2026-07-03T11:22:17+00:00 https://www.vjhemonc.com/video/nbefwk7q8pg-selecting-patients-with-aml-for-transplant-key-considerations-the-role-of-enhanced-mrd-monitoring/ 2026-07-03T11:22:19+00:00 https://www.vjhemonc.com/video/hclmwlqp2ee-key-clinical-outcomes-for-evaluating-treatment-success-in-myelofibrosis/ 2026-07-03T11:22:19+00:00 https://www.vjhemonc.com/video/xxjh1ndn0ry-selecting-the-right-treatment-for-relapsed-diffuse-large-b-cell-lymphoma/ 2026-07-03T11:22:19+00:00 https://www.vjhemonc.com/video/umv-drknxh4-real-world-data-support-bispecific-antibodies-in-large-b-cell-lymphoma/ 2026-07-03T11:22:20+00:00 https://www.vjhemonc.com/video/kpdqscgk7gs-best-practices-for-safely-delivering-bispecific-antibodies-in-lymphoma/ 2026-07-03T11:22:20+00:00 https://www.vjhemonc.com/video/7w2to8xlyt0-ponatinib-consolidation-may-improve-second-treatment-free-remission-in-cml/ 2026-07-03T11:22:21+00:00 https://www.vjhemonc.com/video/bedyiygtu2g-rare-driver-mutations-could-refine-diagnosis-and-management-of-myeloproliferative-neoplasms/ 2026-07-03T11:22:22+00:00 https://www.vjhemonc.com/video/v1fxmhnhsb0-the-evolving-role-of-jak-inhibitors-in-myelofibrosis/ 2026-07-03T11:22:22+00:00 https://www.vjhemonc.com/video/nahjrj7rebk-ctcs-as-a-prognostic-biomarker-in-multiple-myeloma/ 2026-07-03T11:22:22+00:00 https://www.vjhemonc.com/video/vp3845mjybo-barriers-to-implementing-ctcs-in-clinical-practice/ 2026-07-03T11:22:23+00:00 https://www.vjhemonc.com/video/mulgv9gcng4-addressing-unmet-needs-in-follicular-lymphoma-across-the-treatment-journey/ 2026-07-03T11:24:35+00:00 https://www.vjhemonc.com/video/4bwtqykqxfy-sequencing-car-t-cell-therapy-and-bispecific-antibodies-in-relapsed-follicular-lymphoma/ 2026-07-03T11:24:59+00:00